CymaBay Therapeutics, Inc. (CBAY) is priced at $1.80 after the most recent trading session. At the very opening of the session, the stock price was $1.83 and reached a high price of $1.9, prior to closing the session it reached the value of $1.82. The stock touched a low price of $1.8.

CymaBay Therapeutics, Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $13.55 on 05/15/19, with the lowest value was $1.21 for the same time period, recorded on 03/18/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, CymaBay Therapeutics, Inc. shares are logging -86.68% during the 52-week period from high price, and 49.17% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $1.21 and $13.55.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 528432 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the CymaBay Therapeutics, Inc. (CBAY) recorded performance in the market was -7.14%, having the revenues showcasing -2.15% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 122.96M, as it employees total of 24 workers.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.7011, with a change in the price was noted +0.1800. In a similar fashion, CymaBay Therapeutics, Inc. posted a movement of +10.84% for the period of last 100 days, recording 1,546,513 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for CBAY is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Raw Stochastic average of CymaBay Therapeutics, Inc. in the period of last 50 days is set at 91.30%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 88.46%. In the last 20 days, the companys Stochastic %K was 94.64% and its Stochastic %D was recorded 92.16%.

Bearing in mind the latest performance of CymaBay Therapeutics, Inc., several moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -7.14%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -59.91%, alongside a downfall of -85.79% for the period of the last 12 months. The shares increased approximately by 12.54% in the 7-day charts and went down by 15.92% in the period of the last 30 days. Common stock shares were lifted by -2.15% during last recorded quarter.

Read this article:

CymaBay Therapeutics, Inc. (CBAY) is primed for evolution with the beta value of 1.03 - The InvestChronicle